Amdocs Ltd (Amdocs) provides technology software and managed services to communications, Pay TV, entertainment and media industry, and other service providers.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The R&D team of Amdocs focuses on developing new software architecture, modules, and product offerings. It also conducts applied research and software development activities to stay updated with new technologies in the communications and media industry. The company leverages development technologies and methodologies such as DevSecOps, Continuous Integration/Continuous Deployment (CI/CD), and Agile to ensure efficient and cost-effective development and delivery of its solutions. Its R&D activities focus on network control, optimization and orchestration, network functions virtualization technologies, fiber, LTE, small cells, 5G and Wi-Fi, big data analytics, and intelligence capabilities. The company also focuses on developing big data analytics and intelligence capabilities utilizing AI, GenAI, and NLP to enhance consumer and business satisfaction, improve marketing effectiveness, and streamline network operations and experience. Amdocs operates development facilities in the US, the UK, Canada, Brazil, Cyprus, India, Israel, Ireland, Mexico, and the Philippines. In FY2023, the company incurred expenses of US$374.8 million on its R&D, which as a percentage of revenue, stood at 7.7%.